Nureca Limited has informed the exchange regarding Unaudited Financial Results for the quarter ended 30th June ,2025
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.2 pts less than Nifty Microcap 250 and 12.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nureca Limited reported strong revenue growth but sharp profit compression in Q1 FY26. Standalone revenue from operations rose to Rs 317.50 million from Rs 212.15 million in Q1 FY25, a ~50% jump, while consolidated revenue grew ~31% to Rs 341.76 million from Rs 260.46 million. However, standalone profit after tax fell to Rs 5.52 million from Rs 11.95 million (~54% decline), and consolidated PAT dropped to Rs 8.95 million from Rs 16.62 million (~46% decline). Other income collapsed from Rs 81.50 million to Rs 19.08 million on a standalone basis, hurting overall profitability. The board also approved the merger of wholly owned subsidiary Nureca Technologies into the company (appointed date April 1, 2025) and the dissolution of Nureca Healthcare, both pending regulatory approvals. Statutory auditor Singhi & Co. issued an unmodified review opinion on the results.
Despite robust top-line growth, the sharp drop in other income and lower operating leverage led to significantly weaker earnings, which may weigh on near-term investor sentiment. The pending merger and subsidiary restructuring are structural changes to watch but carry execution risk pending NCLT and ROC approvals.